Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia 6Burkitt Lymphoma 5Leukemia, Biphenotypic, Acute 3Prostatic Neoplasms 2Myelodysplastic Syndromes 2Anemia, Refractory, with Excess of Blasts 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Down Syndrome 1Anemia, Refractory 1

Interventions

Cyclophosphamide 10Doxorubicin 6tanespimycin 5Vincristine 5Peripheral Blood Stem Cell Transplantation 5Ifosfamide 5Etoposide 5Cyclosporine 5fludarabine phosphate 4Prednisone 4Methotrexate 4Cytarabine 4Carboplatin 4Bortezomib 4Antilymphocyte Serum 4Vorinostat 3Rituximab 3Methylprednisolone 3Leucovorin 3Irinotecan 3Gemcitabine 3Filgrastim 3Dexamethasone 3Busulfan 3Brentuximab Vedotin 3Biopsy 3Bevacizumab 3merphos 2laromustine 2ixabepilone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Large-Cell, Anaplastic × Hydrocortisone × Clear all
NCT00354107 2018-03-14

Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
5 enrolled 9 charts
Lymphoid

Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡